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Abstract
Background: To investigate a possible prognostic significance of interactions between lymph node
invasion (LNI), synchronous distant metastases (SDM), and venous invasion (VI) adjusted for mode
of detection, Eastern Cooperative Oncology Group performance status (ECOG PS), erythrocyte
sedimentation rate (ESR) and tumour size (TS) in 196 patients with renal cell carcinoma treated
with radical nephrectomy.
Methods: Median follow-up was 5.5 years (mean 6.9 years; range 0.01–19.4). The mode of
detection, ECOG PS, ESR and TS were obtained from the patients' records. Vena cava invasion and
distant metastases were detected by preoperative imaging. The surgical specimens were examined
for pathological stage, LNI and VI.
Results: The univariate analyses showed significant impact of VI, LNI, SDM, ESR and TS (p < 0.001),
as well as mode of detection (p = 0.003) and ECOG PS (p = 0.002) on cancer specific survival. In
multivariate analyses LNI was significantly associated with survival only in patients without SDM or
VI (p < 0.001) with a hazard ratio of 9.0. LNI lost its prognostic significance when SDM or VI was
present.
Conclusion: Our findings underline the prognostic importance of the status of the lymph nodes.
LNI, SDM, ESR, and VI were independently associated with cancer specific survival after radical
nephrectomy. LNI provided the strongest prognostic information for patients without SDM or VI
whereas SDM and VI had strongest impact on survival when there was no nodal involvement.
Background
Renal cell carcinoma (RCC) is the third most common
genitourinary malignancy and accounts for 3% of cancer
in adults. About 25% of patients with RCC present with
metastatic disease; either lymph node infiltration, simul-
taneous distant metastases or both [1].
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The wide application of imaging modalities has increased
the incidental detection of RCC and changed its natural
history over the last two decades. However, it has been dif-
ficult to find reliable prognostic factors particularly for
locally advanced and metastatic RCC. The prognostic
value of mode of presentation and Eastern Cooperative
Oncology Group performance status (ECOG PS) in RCC
have been controversial in earlier studies [2,3]. Even
though ECOG PS and symptoms at presentation were of
independent prognostic significance, the combination of
those two variables in prognostic models did not improve
the capability to predict RCC specific mortality [3]. The
contribution of tumour size (TS), erythrocyte sedimenta-
tion rate (ESR) and venous invasion (VI) in prediction of
prognosis have been a matter of debate in several studies
[2,4-7]. According to recent studies the presence but not
the extent of venous invasion was independently corre-
lated with the cancer-specific survival [8,9].
One of the most important prognostic factors in RCC is
lymph node invasion (LNI). However, the prognostic dis-
crimination between pN1 and pN2 categories in the 2002
TNM system has been questioned. A recent study con-
cludes that the percentage of positive nodes and a thresh-
old number of four rather than one positive lymph node
correlated significantly with clinical outcome [10]. The
appropriateness of the pNx/pN0 grouping and prognostic
relevance in a multivariate setting has also been discussed
[11].
To our knowledge the possible impact on cancer specific
survival (CSS) of interactions between LNI, synchronous
distant metastases (SDM) and VI have not yet been fully
studied. We hypothesized that putatively significant inter-
actions between these variables could contribute in pre-
diction of outcome for patients with RCC after radical
nephrectomy.
To test this hypothesis we examined the relationship
between cancer specific survival and LNI, SDM, and VI,
including possible interactions between these variables,
with adjustment for mode of detection, Eastern Coopera-
tive Oncology Group performance status, erythrocyte sed-
imentation rate and continuously coded tumour size.
Methods
Patients
The patient material in this retrospective and population-
based series is described in detail elsewhere [12]. Briefly, a
total of 196 consecutive patients who underwent radical
nephrectomy for renal cell carcinoma during the years
1985 to 1994 were included in the study. Tumour staging
was done according to the 2002 TNM classification sys-
tem using the American Joint Committee on Cancer
(AJCC) stage grouping [13].
All patients were given a thorough clinical examination
preoperatively, including imaging techniques. Bone scans
were performed in those with symptoms and signs of skel-
etal involvement. When a thrombus of the inferior vena
cava was suspected, both ultrasound and an inferior cavo-
gram were done in order to better define the thrombus
level.
Approval to use the biological material for research pur-
poses was granted in 2004 by the local authority at Karl-
stad Central Hospital in Sweden according to Swedish
regulations. In Norway the appropriate Norwegian
authority, Norwegian Social Science Data Services, recog-
nized this approval. The study was carried out in accord-
ance with the standards of World Medical Association
Declaration of Helsinki as revised in 2008.
Treatment
Standard radical nephrectomy was done in all patients. A
thrombus of the vena cava was found in 15 patients and
treated with cavotomy and thrombectomy. The clinical
lymph node staging was performed based on preoperative
CT images of the abdomen and/or the peroperative find-
ings. In cases with enlarged or palpable lymph nodes
between the aorta and vena cava or other sites, additional
lymph node dissection was done. Extensive radical retro-
peritoneal lymph node dissection was not performed.
Only 14 of the surgical specimens had a sufficient number
of negative nodes (eight) to be classified as pN0 category.
Accordingly 161 of the patients were pNx (clinically N0).
Methods
Clinical information regarding age, sex, Eastern Coopera-
tive Oncology Group performance status [14], erythrocyte
sedimentation rate obtained preoperatively according to
the Westergren method (reference interval: <28 mm/h)
[15,16], metastases and final disease status were extracted
from the patient's clinical records.
According to the mode of detection patients were classi-
fied in two groups: incidental and symptomatic. Tumours
diagnosed during abdominal imaging studies for signs
and symptoms unrelated to RCC were classified as inci-
dental.
The clinical records and pathology reports were reviewed
to determine stage, size and type of the primary tumour.
Continuously coded tumour size (CCTS) was used in all
analyses and given in cm by measuring the greatest diam-
eter. The nephrectomy specimens were examined his-
topathologically in a uniform manner. Histological
examination included searching for invasion of the
tumour into perinephric or peripelvic fat, any possible
involvement of the adrenals or spread beyond Gerota's
fascia. Careful examination of the regional lymph nodesBMC Urology 2008, 8:19 http://www.biomedcentral.com/1471-2490/8/19
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was done. One urologic pathologist (LB) performed the
histological subtyping of the RCC according to the Hei-
delberg classification guidelines [17]. Venous invasion
was registered as no venous invasion (pV0), renal vein
invasion (RVI) (pV1) or vena cava invasion (VCI) (pV2)
and dichotomised (pV0 vs. pV1+pV2) in all except
descriptive analyses, for compatibility with most previous
reports. RVI was diagnosed when there was invasion by
tumour of major extra renal veins found microscopically
in transverse slices of the vein. In patients with VCI, the
tumour thrombus did not adhere to the intima of the vena
cava.
Follow-up
The postoperative clinical follow-up was done at each
hospital according to established protocols, including
clinical and radiological examination at regular intervals
for a median of 3 years (range 0.1–11.5). Information of
local recurrence, metastases and final status were extracted
from hospital files or from information obtained by con-
tacting the local general practitioners. The cause of death
was determined from clinical records and death certifi-
cates. Deaths from other causes than RCC were censored.
We obtained information of surviving patients by search-
ing The Swedish Updated Population Register and by con-
tacting the local general practitioners (GPs). The clinical
status was complete up to 30 April 2004 when the study
was ended. Thus, the patients could be assigned a date of
death or identified as being alive with or without diag-
nosed recurrent disease. Median and mean follow up
period for the whole population studied was 5.5 years and
6.9 years (range 0.01–19.4), respectively. Median follow
up was 13.9 years for patients alive at the end of the study.
Statistical procedures
Preliminary analyses included descriptive statistics and
assessment of associations of LNI, SDM and VI with TS,
presenting symptoms and ECOG PS, by cross tabulations,
with exact χ2-, linear by linear association or Mann-Whit-
ney tests. The relationships of CSS to LNI, SDM and VI
were investigated by multiple Cox regression analysis for
CSS, including all two-way interactions and adjusting for
ESR, CCTS (continuously coded), presenting symptoms
and ECOG PS. All statistical analyses were accomplished
in SPSS 14.0 (SPSS Inc., Chicago, USA). All tests were two-
sided with a significance level at 0.05.
Results
Predictive factors
The clinicopathological characteristics of the 196 patients
in the study are detailed in Table 1. In the symptomatic
group the leading symptom was haematuria in 64, weight
loss associated with asthenia 14, or flank pain 42. Abnor-
mal blood tests like elevated erythrocyte sedimentation
rate, anemia or elevated haemoglobin were the main
causes for detection of RCC in 25, 8 and 2 patients, respec-
tively. At presentation 45 patients harboured distant
metastases and about three quarters had metastases in
multiple sites; the most frequent sites were lungs (24
patients), the skeleton (10), the liver (5), the brain or the
spine (4) and other sites (14).
Lymph node invasion was diagnosed in 21 of 196 patients
of whom 16 had SDM. In ten patients with LNI there was
also venous invasion. Of 15 patients with vena cava inva-
sion seven patients had SDM and six had regional local
lymph node metastases. Venous invasion carried a signif-
icantly higher risk for having SDM (p = 0.003) as well as
LNI (p = 0.014). Such patients also had a significantly
higher rate of lung metastases as 16 patients with VI had
lung metastases as compared to 9 patients without VI (p <
0.001). Additionally, venous invasion was significantly
associated with tumour size (p < 0.001).
Univariate analyses
As depicted in Table 2 factors such as age and gender were
not associated with CSS. The mode of presentation and
performance status was significant prognostic variables (p
= 0.003 and p = 0.002, respectively). High ESR and large
TS were inversely related to survival (p < 0.001). LNI, SDM
and VI were also significantly related to CSS (p < 0.001)
with hazard ratios of 5.4, 6.6 and 2.3, respectively.
Multivariate analyses
In multivariate Cox regression analysis, only LNI, SDM, VI
and ESR remained independent prognostic factors (Table
3). Lymph node metastases had a significant impact on
CSS only for patients in whom neither distant metastases
nor venous invasion were present. In patients without
lymph node metastases, we were able to define prognostic
subgroups of patients based on multivariate analysis by
including different combinations of SMD and VI.
A Kaplan-Meyer analysis of CSS in node positive, as well
as four combinations of SDM and VI in node negative
patients is depicted in Figure 1.
Discussion and conclusion
This long-term, population-based study is including con-
secutively operated patients with RCC from a well-defined
region in Sweden. Even though the number of patients in
the study is limited, it consists of a complete cohort of
RCC patients as very few patients were referred out of the
region for operation. The limitation of the study is its ret-
rospective design and the enrolment of patients who
underwent radical nephrectomy for RCC in the period
1985 to 1994. Since then more tumours are detected inci-
dentally and the standard of care has changed. However,
the proportion of incidentally detected RCC in the present
study is similar to contemporary series [18,19]. Also, theBMC Urology 2008, 8:19 http://www.biomedcentral.com/1471-2490/8/19
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Table 1: Clinical and pathologic features in 196 patients with renal cell carcinoma.
Features Clear cell carcinoma Papillary carcinoma All subtypesa
No. of cases 172 (87.8) 19 (9.7) 196 (100)
Mean age (years) 66.6 62.4 66.4
Gender
n Male/Female 95/77 13/6 110/86 (56.1)
Pathologic tumour size (cm)
Median (range) 7.0 (1.5 – 26.0) 8 (3.0–20.0) 7 (1.5 – 26.0)
Mode of presentation
Symptomatic/Incidental 144/28 17/2 165/31 (84.2)
ECOG performance status:
0 109 (63.4) 12 (63.2) 125 (63.8)
1 52 (30,2) 6 (31.6) 58 (29.6)
2 11 (6.4) 1 (5.3) 13 (6.6)
ESR
< 28 mm 88 (51.2) 10 (52.5) 103 (52.6)
≥ 28 mm 84 (48.8) 9 (47.3) 95 (48.5)
RCC Stage groups (TNM, 2002)
I 52 (30.2) 7 (36,8) 62 (31.6)
II 24 (14.0) 5 (26,3) 29 (14.8)
III 48 (27.9) 3 (15.8) 53 (27.0)
IV 48 (27.9) 4 (21.1) 52 (27.0)
Primary pathological tumour stage (pT, 2002)
pT1a 18 (10.5) 3 (15,8) 22 (11.2)
pT1b 39 (22.7) 5 (26.3) 46 (23.5)
pT2 28 (16.3) 6 (31.6) 34 (17.3)
pT3a 28 (16.3) 0 (0) 29 (14.8)
pT3b 48 (28.0) 5 (26.3) 54 (27.6)
pT3c 0 (0) 0 (0) 0 (0)
pT4 11 (6.4) 0 (0) 11 (5.6)
Pathologic stage of lymph nodes (N, 2002)
pN x 141 (82.0) 15 (79.0) 161 (82.1)
pN 0 14 (8.1) 0 (0) 14 (7.1)
pN 1 10 (5.8) 2 (11.0) 12 (6.1)
pN 2 7 (4.1) 2 (11.0) 9 (4.6)
SDM (M, 2002)
M 0 131 (76.1) 15 (79.0) 151 (77.0)
M + (single) 9 (5.2) 1 (5.3) 10 (5.1)
M + (multiple) 32 (18.6) 3 (15.8) 35 (17.9)
Venous invasion (VI = pV1+pV2)
pV 0 122 (70.9) 14 (73.7) 140 (71.4)
pV 1 (renal vein) 36 (20.9) 4 (21.1) 41 (20.9)
pV 2 (vena cava) 14 (8.1) 1 (5.3) 15 (7.7)
Unless stated otherwise, values shown represent numbers of patients, with percentages in parentheses.
aIncluding chromophobic carcinoma (n = 5)BMC Urology 2008, 8:19 http://www.biomedcentral.com/1471-2490/8/19
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size of the data set limited the number of adjustment var-
iables that could be included in the multivariate survival
model. The results of this model are, however, largely con-
firmed by a simple Kaplan-Meier analysis. Also, as a sen-
sitivity analysis we have re-run the model including
pTstage (1–2 vs. 3–4). Generally, the contrasts between
LNI, VI and SDM categories were not considerably differ-
ent in this enlarged model (data not shown).
The strength of the study is its long-term follow-up and
the high quality of follow-up data that were obtained
from institutions providing health service, local GPs or
population register.
The symptoms of RCC at presentation have been associ-
ated with poor outcome [3,18,20]. In univariate analysis
we did find a survival advantage in favour of incidentally
detected RCC compared with symptomatic RCC. How-
ever, in keeping with the findings of Ishimura et al. [20]
and Gudbjartsson et al. [21], the independent prognostic
significance of mode of presentation was not confirmed
in multivariate analysis. In agreement with other studies,
[4,22] we found that elevated ESR at presentation was
associated with more aggressive disease and poorer out-
come for both clear cell and papillary RCC (data not
shown). Contrary to the study of Sengupta et al. [4] the
frequency of elevated ESR among our patients was not sig-
nificantly different between these two histological sub-
types.
In general, distant metastases at operation have a pro-
found adverse impact on survival after radical nephrec-
tomy for RCC. However, some patients with SDM have a
more indolent disease course after radical nephrectomy
and are expected to survive for more than five years. In our
study 10% of patients were alive after seven years of fol-
low-up. The patients with metastases in lung or bone had
a poorer prognosis than those with metastases limited to
other organs. The lung was the most prevalent site of
metastases in one third of the patients in whom the
tumour invaded the renal veins or the vena cava. Confirm-
ing the findings of Ljungberg et al. [6] and Zisman et al
[23], these studies are lending support to the notion that
most metastases in such patients probably develop hae-
matogenous rather than through the lymphatic system.
Lymph node invasion has been shown in several studies
to adversely affect the survival after nephrectomy for RCC
[7,23-25]. The reported incidence of LNI among patients
treated with radical nephrectomy and lymph node dissec-
Table 2: Univariate analysis of cancer specific survival related to clinicopathological variables in 196 patients operated with radical 
nephrectomy for renal cell carcinoma.
UNIVARIATE ANALYSIS Cancer specific survival
HR 95% CI p-value
Primary pathological tumour stage (pT, 2002)
pT1a ref.
pT1b 5.5 0,7 – 42.7 0.102
pT2 11.5 1,5 – 87.6 0.018
pT3a 16.3 2.2 – 123.5 0.007
pT3b 21.5 2.9 – 157.1 0.003
pT4 63.5 8.1 – 498.2 <0.001
Gender male ref. 0.74 0.48 – 1.14 0.170
Age (continuous), per 5 years 1.01 0.91 – 1.11 0.908
Continuously coded tumour size (CCTS), per 10 cm 2.98 1.87 – 4.75 <0.001
Mode of detection (Incidental vs. Symptomatic) 3.89 1.58 – 9.59 0.003
ECOG PS (≥ 1 vs. 0) 1.94 1.26 – 2.98 0.002
ESR (≥ 28 mm vs. < 28 mm) 3.36 2.11 – 5.35 <0.001
LNI (pN 1/2 vs. pN x/0) 5.38 3.17 – 9.10 <0.001
SDM (M + vs. M 0) 6.56 4.17 – 10.33 <0.001
VI (pV 1/2 vs. pV 0) 2.33 1.51 – 3.60 <0. 001BMC Urology 2008, 8:19 http://www.biomedcentral.com/1471-2490/8/19
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tion is varying from 3.3% to 14.2% [23,26] depending on
the study population and the time period. In the era of
modern imaging techniques, the incidence of positive
lymph nodes has decreased to 3% to 5%. In the present
series, 21 patients (10.7%) had lymph node metastases.
The relatively high incidence of positive nodes is reflecting
the patient selection as 45 patients with SDM underwent
radical nephrectomy. Three quarters of the node positive
patients had synchronous distant metastases, which are in
line with the findings of an autopsy study [27]. Patients
harbouring lymph node metastases had a sinister progno-
sis and in these patients the presence or absence of SDM
and VI did not influence the outcome. However, in lymph
node negative patients we were able to define subgroups
with significant different survival according to presence
and absence of SDM or VI or both. Patients with tumour
invasion of the vena cava or the renal veins as the only
adverse feature had a significantly longer survival than
those with only distant metastases. Nesbitt et al. [24] and
Tsuji et al. [25] reported that in patients operated for RCC
with thrombus in the vena cava, distant metastases at the
time of operation did not significantly decrease the sur-
vival for those who were node negative whereas patients
with lymph node metastases had a significant shorter sur-
vival. Ljungberg et al. [6] performed preoperative staging
and no extensive lymph node dissection and reported a
significantly shorter CSS of patients with SDM and VI
compared with those with SDM only. However, it remains
unclear whether the status of the lymph nodes was
included in the analysis.
Only few studies have analysed survival by comparing
N1/N2M1 and N0M1 disease; most patients with M1 dis-
ease are grouped together regardless of lymph node status.
In the multivariate analysis of interactions of SMD, VI and
LNI on survival, LNI showed a significant impact on sur-
vival only for the patients in whom we found no distant
metastases or venous invasion. In this subgroup of
patients there was a hazard ratio of 9.0 for later death of
RCC. This finding implies that once RCC has spread to the
lymphatic system the risk of haematogenous spread to
other regions is high, and it is likely that few patients
would benefit from an extensive lymph node dissection.
In accordance with other reports, the impact of VI on sur-
vival was highest for patients free from nodal and distant
metastases, and was insignificant in patients with both
LNI and SDM [7,28].
Our findings underline the prognostic importance of the
status of the lymph nodes. LNI, SDM, ESR, and VI were
independently associated with CSS after radical nephrec-
tomy. LNI provided the strongest prognostic information
for patients without SDM or VI whereas SDM and VI had
strongest impact on survival when there was no nodal
involvement. These findings imply that once RCC has
spread to the lymphatic system the risk of haematogenous
Table 3: Multivariate survival analysis of interactions between clinicopathological variables and cancer specific survival in 196 patients 
operated with radical nephrectomy for renal cell carcinoma.
MULTIVARIATE Cancer specific survival
ANALYSES HR 95% CI p-value
Lymph Node Involvement present
VI present, SDM present 0.55 0.23 – 1.30 0.173
VI present, SDM absent 2.78 0.80 – 9.64 0.108
VI absent, SDM present 1.77 0.74 – 4.21 0.197
VI absent, SDM absent 8.96 3.27 – 24.56 <0.001
Venous invasion present
LNI present 0.63 0.25 – 1.64 0.349
LNI absent 2.05 1.22 – 3.43 0.006
Synchronous distant metastases present
LNI present 0.93 0.32 – 2.74 0.894
LNI absent 4.71 2.68 – 8.27 <0.001
CCTS (Tumour size per 10 cm) 1.49 0.75 – 2.95 0.256
ESR (≥ 28 mm vs. <28 mm ref.) 1.94 1.15 – 3.26 0.012
ECOG PS (≥ 1 vs. 0) 1.47 0.93 – 2.33 0.099
Mode of detection (Symptomatic vs. Incidental) 0.66 0.25 – 1.71 0.392BMC Urology 2008, 8:19 http://www.biomedcentral.com/1471-2490/8/19
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spread to other regions is high and it is likely that few
patients would benefit from extensive lymph node dissec-
tion.
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